Greenland Mines Ltd
About Greenland Mines Ltd
Greenland Mines Ltd develops essential medicines for the treatment of chronic diseases - cancer, cardiovascular, and neurodegenerative disorders. The Company operates as a single reporting segment focused on developing essential medicines for these chronic diseases. The Company has acquired two licensed platforms: a generic drug portfolio and a biosimilar biologics platform that uses biologic therapies to treat cancer, and proprietary patented technologies involving melanocortin receptor-binding molecules and a gene therapy platform that introduces a therapeutic protein called Klotho inside the body to treat neurodegenerative diseases.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Net income
- -$10.6M
- Total assets
- $9.6M
- Market cap
- $37.2M
Source: SEC EDGAR · updated Jun 8, 2026
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $37.2M
- Shares outstanding
- 120.1M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Mar 12, 2026
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $10.6M.
- Trading 40% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Greenland Mines Ltd.
Write a review
News about Greenland Mines Ltd
News & sentiment via Polygon.io
